Their analysis also suggested a protective effect of ARBs against AP; therefore, it may be reasonable to prescribe ARBs for patients who developed AP due to ACE-I if they have a strong indication for renin-angiotensin-aldosterone system (RAAS) blockade such as cardiomyopathy or proteinuric kidney disease [12]. The gene discussed is REN; the disease is cardiomyopathy.